RxDoctor Payments Data

Beverly Conder, NP

Nurse Practitioner · Huntersville, NCNPI 1619084647

Payments from drug & device makers

$7,680in general payments, 2019–2025

Across 281 payments — averaging $27.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Johnson & Johnson$826
  • Novartis$749
  • AstraZeneca$513
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$425
  • Merck$375
  • plus $2K from 15 others

What the payments were for

  • Travel & lodging$1,60121%
  • Food & beverage$6,03879%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,680 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$41,405
Medicare patients
150
Services billed
421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan508$489,276
VyndamaxTafamidis15$335,218
JardianceEmpagliflozin144$168,555
EliquisApixaban105$106,781
FarxigaDapagliflozin Propanediol96$90,888
XareltoRivaroxaban25$26,533
CorlanorIvabradine Hcl16$17,647
BrilintaTicagrelor19$8,940
Metoprolol Succinate404$4,942
Torsemide212$4,446
Dofetilide12$2,133
Potassium Chloride96$1,653
Spironolactone320$1,633
Ranolazine ErRanolazine11$1,445
Carvedilol150$1,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$749$489,276508 claims
PfizerVyndamax, Eliquis$262$442,000120 claims
Boehringer IngelheimJardiance$300$168,555144 claims
AstraZenecaFarxiga, Brilinta$513$99,828115 claims
Johnson & JohnsonXarelto$826$26,53325 claims
AmgenCorlanor$237$17,64716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Huntersville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →